Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine | Reuters

Sanofi has offered commitments to EU antitrust regulators to stop disparaging rival flu vaccine Fluad, including public statements affirming equal efficacy and refraining from negative comparisons for two years across Germany and France. The move preempts potential fines up to 10% of global turnover for alleged anti-competitive conduct.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.